<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03563417</url>
  </required_header>
  <id_info>
    <org_study_id>ISCHEMIA-CTO Trial</org_study_id>
    <nct_id>NCT03563417</nct_id>
  </id_info>
  <brief_title>ISCHEMIA-CTO Trial - Revascularisation or Optimal Medical Therapy of CTO</brief_title>
  <acronym>ISCHEMIA-CTO</acronym>
  <official_title>International Randomized Trial on the Effect of Revascularization or Optimal Medical Therapy of Chronic Total Coronary Occlusions With Myocardial Ischemia - ISCHEMIA-CTO Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aarhus University Hospital Skejby</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aarhus University Hospital Skejby</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study design&#xD;
&#xD;
      Prospective randomized open labeled multicenter study&#xD;
&#xD;
      Hypotheses&#xD;
&#xD;
        1. In asymptomatic patients with ≥ 10% of myocardial ischemia: PCI (Percutaneous Coronary&#xD;
           Intervention) with latest generation of drug eluting stents is superior to optimal&#xD;
           medical therapy in terms of relative reduction in MACCE (Major Adverse Cardiovascular&#xD;
           and Cerebrovascular events).&#xD;
&#xD;
        2. In symptomatic patients with ≥ 5% of myocardial ischemia: PCI with latest generation of&#xD;
           drug eluting stents is superior to optimal medical therapy (OMT) in terms of improved&#xD;
           life quality measured as an increase of SAQ (Self Assessment Questionnaire) score of 8&#xD;
           points after 6 months.&#xD;
&#xD;
      Inclusion Criteria&#xD;
&#xD;
        -  CTO in native coronary artery&#xD;
&#xD;
        -  Myocardial ischemia in a territory supplied by CTO assessed by nuclear imaging.&#xD;
&#xD;
        -  Age ≥18 yrs.&#xD;
&#xD;
        -  Able to provide written Informed consent and willing to comply with the specified&#xD;
           follow-up contacts&#xD;
&#xD;
        -  Target artery ≥ 2.5 mm&#xD;
&#xD;
      Prior to randomization all patients undergo 3 months of OMT. Subsequently the population will&#xD;
      be divided into:&#xD;
&#xD;
      Cohort A: Asymptomatic (CCS &lt; 2 and SAQ QoL &gt; 60) patients with myocardial ischemia (≥ 10% of&#xD;
      LV) in a territory supplied by CTO&#xD;
&#xD;
      Cohort B: Symptomatic patients (CCS class ≥ 2 and/or SAQ QoL score ≤ 60 after treating non&#xD;
      CTO lesions and after OMT) with Myocardial ischemia (5% of LV) in a territory supplied a CTO&#xD;
&#xD;
      Cohort C: patients enrolled but not randomized in cohort A or B&#xD;
&#xD;
      Exclusion criteria (for both cohort A and B)&#xD;
&#xD;
        -  NSTEMI or STEMI within 1 month&#xD;
&#xD;
        -  Coronary anatomy not suitable for CTO-procedure&#xD;
&#xD;
        -  Coronary artery disease involving the left main/three-vessel disease with indication for&#xD;
           CABG following heart team conference&#xD;
&#xD;
        -  Life expectancy &lt; 2 years&#xD;
&#xD;
        -  Severe chronic pulmonary disease (FEV1 &lt; 30 % of predicted value)&#xD;
&#xD;
        -  Contraindication to dual anti-platelet therapy&#xD;
&#xD;
        -  Pregnancy&#xD;
&#xD;
        -  eGFR &lt; 30 mL/min/1.73 m2&#xD;
&#xD;
        -  In multi-vessel disease: if it is deemed unsafe to treat the non-CTO lesion first.&#xD;
&#xD;
        -  Severe valvular heart disease&#xD;
&#xD;
      Primary endpoint&#xD;
&#xD;
      Cohort A: Composite endpoint of MACCE (all-cause mortality, stroke, any myocardial&#xD;
      infarction, clinically driven revascularization*), hospitalization for heart failure or&#xD;
      incidence of malignant arrhythmias.&#xD;
&#xD;
      *CCS class ≥ 2 and/or QoL score &lt; 60. Same criteria used as for allocation to Cohort B&#xD;
&#xD;
      Cohort B: SAQ Quality of Life Assessment after 6 months.&#xD;
&#xD;
      Number of patients&#xD;
&#xD;
      1,560 (1200 in cohort A/360 in cohort B&#xD;
&#xD;
      Follow up time&#xD;
&#xD;
      Cohort A: 5 years Cohort B: 6 months&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A chronic total occlusion (CTO) is observed in up to (1) 30 % of patients undergoing&#xD;
      diagnostic coronary angiography. The presence of a CTO is associated with worse outcome&#xD;
      compared to non-occlusive coronary artery disease.&#xD;
&#xD;
      Percutaneous Coronary Intervention (PCI) treatment of CTO lesions has gained much attention&#xD;
      over the last decade due to introduction of new techniques and devices resulting in high&#xD;
      success rates in dedicated centers. However the scientific evidence is mainly based on&#xD;
      observational studies and expert consensus. The current European and American guidelines on&#xD;
      revascularization does not provide any clear recommendations how to manage patients with CTO.&#xD;
&#xD;
      The indication of treating a CTO lesion, or any other lesion with PCI for that matter, is&#xD;
      either to relieve symptoms or improve prognosis. However, to date, there are no randomized&#xD;
      clinical trials showing any prognostic benefit from CTO revascularization. Data from&#xD;
      randomized clinical trials are also scarce regarding improvement of symptoms and Quality of&#xD;
      life (QoL). In the recently presented DECISION-CTO study, patients were randomized to PCI vs.&#xD;
      OMT, and the study failed to demonstrate a prognostic or symptomatic benefit of PCI vs. OMT.&#xD;
      However, the study was prematurely terminated due to slow inclusion rate and had a high&#xD;
      crossover rate and a high proportion did not have a quality of life score at follow-up. The&#xD;
      fact that both the Decision CTO and the Euro CTO trial failed to include the pre-specified&#xD;
      number of patients, makes it difficult to draw any conclusions on how to treat these&#xD;
      patients. The preliminary results from both trials indicate that CTO PCI seems to be a safe&#xD;
      procedure and might improve symptoms and QoL. In the randomized EXPLORE trial, patients with&#xD;
      ST-elevation myocardial infarction (STEMI)and a concomitant CTO in a non infarct related&#xD;
      artery was investigated. This study showed no benefit in terms of improving left ventricular&#xD;
      function due to CTO-PCI of the concomitant CTO, although the procedure was safe.&#xD;
&#xD;
      Meta-analysis of observational studies comparing the prognosis after successful vs.&#xD;
      unsuccessful CTO PCI indicate prognostic and symptomatic benefit of successful CTO PCI.&#xD;
      However, these studies often lack data regarding ischemia burden and viability. The fact that&#xD;
      the non-successful PCI patients consistently in these studies have higher risk profile,&#xD;
      indicating the presence of residual confounders not accounted for in the multivariate&#xD;
      statistical models, makes the interpretation of these data in a clinical setting difficult.&#xD;
      The non-randomized FACTOR trial demonstrated a positive outcome for quality of life, but only&#xD;
      in symptomatic patients. Data from the OPEN-CTO registry demonstrated an improvement of the&#xD;
      Seattle Angina Questionnaire for quality of life by 10.8 points after a successful&#xD;
      CTO-procedure. In addition to symptomatic improvement, a successful CTO procedure can reduce&#xD;
      the amount of myocardium susceptible to ischemia in patients with at least mild to moderate&#xD;
      ischemia at baseline and by that the prognosis can be improved (mortality, myocardial&#xD;
      infarction, ventricular arrhythmias).&#xD;
&#xD;
      Hence, the interventional management of CTO lesions must address whether it is indicated on&#xD;
      symptomatic and/or prognostic basis. These questions have not been sufficiently addressed in&#xD;
      the previous trials and we need evidence from randomized clinical trials on how to treat&#xD;
      these patients. We therefore designed this randomized clinical trial addressing the impact of&#xD;
      CTO PCI on outcome. Patients are included in 2 different patient cohorts depending on level&#xD;
      of symptoms and level of myocardial ischemia. From previous studies, we know that it is most&#xD;
      probably only patients with at least moderate myocardial ischemia who will benefit from CTO&#xD;
      PCI in terms of improving MACCE, and only symptomatic patients who will benefit with regard&#xD;
      to improvement of quality of life following CTO PCI.&#xD;
&#xD;
      Before entering the study all patients will be subject to a 3-month period with titration of&#xD;
      optimal medical therapy. Hereafter the patients will be eligible for inclusion in one of two&#xD;
      cohorts based on level of ischemia and presence of symptoms:&#xD;
&#xD;
      Cohort A: Comprise CTO patients who are asymptomatic (CCS class &lt;2 and SAQ QoL&gt; 60) but have&#xD;
      moderate myocardial ischemia (&gt;10% of the left ventricle) on MR or rubidium-PET. These&#xD;
      patients will be randomized to CTO PCI or OMT and followed up to 10 years.&#xD;
&#xD;
      Cohort B: Comprise symptomatic CTO patients (CCS class ≥ 2 and/or SAQ QoL score ≤ 60) with at&#xD;
      least 5% reversible ischemia. These patients will be randomized to CTO PCI or OMT. The&#xD;
      patients randomized to OMT will be offered CTO PCI procedure 6 months after randomization&#xD;
      following assessment of Seattle Angina Questionnaire quality of life score.&#xD;
&#xD;
      Cohort C - Patients enrolled but not eligible for randomization All patients enrolled at&#xD;
      baseline but who do not meet the criteria described in cohort A and B for randomization.&#xD;
      Registry based follow-up (optional) is performed at the same time points as in Cohort A.&#xD;
&#xD;
      This is the first randomized study that addresses improvement of prognosis and quality of&#xD;
      life following PCI of CTO lesions specifically.&#xD;
&#xD;
      The purpose of this study is twofold:&#xD;
&#xD;
        1. Investigate the outcome of PCI vs. optimal medical therapy of CTO lesions in patients&#xD;
           with significant myocardial ischemia (≥ 10%) without symptoms&#xD;
&#xD;
        2. Investigate the outcome of PCI vs. optimal medical therapy of CTO lesions in patients&#xD;
           with symptoms and mild to moderate myocardial ischemia (≥5%).&#xD;
&#xD;
      Hypotheses&#xD;
&#xD;
        1. In asymptomatic patients with ≥ 10% of myocardial ischemia: PCI with latest generation&#xD;
           of drug eluting stents is superior to optimal medical therapy in terms of outcome&#xD;
           measured as 30% relative reduction in Major Adverse Cardiovascular and Cerebrovascular&#xD;
           events (MACCE).&#xD;
&#xD;
        2. In symptomatic patients with ≥ 5% of myocardial ischemia: PCI with latest generation of&#xD;
           drug eluting stents is superior to optimal medical therapy in terms of improved life&#xD;
           quality measured as an increase of SAQ score of 8 points after 6 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 6, 2018</start_date>
  <completion_date type="Anticipated">November 1, 2032</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2028</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Major Adverse Cerebral and Cardiovascular Events</measure>
    <time_frame>5 Year</time_frame>
    <description>Primary outcome in the Cohort A.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quality of life - Seattle Angina Questionnaire</measure>
    <time_frame>6 months</time_frame>
    <description>Primary outome in the Cohort B</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1560</enrollment>
  <condition>Ischemic Heart Disease</condition>
  <condition>Chronic Total Occlusion of Coronary Artery</condition>
  <arm_group>
    <arm_group_label>PCI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>OMT</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Percuteneous Coronary Intervention</intervention_name>
    <description>PCI of Chronic Total Occlusions</description>
    <arm_group_label>PCI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Optimal Medical Therapy</intervention_name>
    <description>Initiation and titration of optimal medical therapy in the control arm.</description>
    <arm_group_label>OMT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  CTO in native coronary artery&#xD;
&#xD;
          -  Myocardial ischemia in a territory supplied by CTO assessed by nuclear imaging.&#xD;
&#xD;
          -  Age ≥18 yrs.&#xD;
&#xD;
          -  Able to provide written informed consent and willing to comply with the specified&#xD;
             follow-up contacts.&#xD;
&#xD;
          -  Target artery ≥ 2.5 mm&#xD;
&#xD;
        Prior to randomization all patients undergo 3 months of OMT. Subsequently the population&#xD;
        will be divided into:&#xD;
&#xD;
        Cohort A: Asymptomatic (CCS &lt; 2 and SAQ QoL &gt; 60) patients with myocardial ischemia (≥ 10%&#xD;
        of LV) in a territory supplied by CTO&#xD;
&#xD;
        Cohort B: Symptomatic patients (CCS class ≥ 2 and/or SAQ QoL score ≤ 60 after treating non&#xD;
        CTO lesions and after OMT) with Myocardial ischemia (5% of LV) in a territory supplied a&#xD;
        CTO assess by nuclear imaging.&#xD;
&#xD;
        Cohort C: Screening population not eligible for randomization in cohort A or B&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  NSTEMI or STEMI within 1 month&#xD;
&#xD;
          -  Coronary anatomy not suitable for CTO-procedure&#xD;
&#xD;
          -  Coronary disease involving the left main/three vessel disease with indication for CABG&#xD;
             following heart team conference.&#xD;
&#xD;
          -  Life expectancy &lt; 2 years&#xD;
&#xD;
          -  Severe chronic pulmonary disease (FEV1 &lt; 30 % of predicted value)&#xD;
&#xD;
          -  Contraindication to dual anti-platelet therapy&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  eGFR &lt; 30 mL/min/1.73 m2&#xD;
&#xD;
          -  In multi-vessel disease: if it is deemed unsafe to treat the non-CTO lesion first.&#xD;
&#xD;
          -  Severe valvular heart disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Evald Christiansen, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aarhus University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Evald Christiansen, MD PhD</last_name>
    <phone>+45 78452028</phone>
    <email>evald.christiansen@dadlnet.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Emil N Holck, MD</last_name>
    <phone>+45 31419472</phone>
    <email>eh@clin.au.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Aarhus University Hospital</name>
      <address>
        <city>Aarhus N</city>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Evald H Christiansen, MD</last_name>
      <phone>+45 61655176</phone>
      <email>evalchri@rm.dk</email>
    </contact>
    <contact_backup>
      <last_name>Emil N Holck, MD</last_name>
      <email>eh@clin.au.dk</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hans Henrik TIlsted, MD</last_name>
      <email>hans-henrik.tilsted@regionh.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gentofte Hospital</name>
      <address>
        <city>Hellerup</city>
        <zip>2900</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Niels Thue Olsen, MD</last_name>
      <email>niels.thue.olsen@regionh.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karsten Veien, MD</last_name>
      <email>karsten.veien@rsyd.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zealand University Hospital</name>
      <address>
        <city>Roskilde</city>
        <zip>4000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ole Havndrup, MD</last_name>
      <email>oha@regionsjaelland.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>North-Estonia Medical Centre</name>
      <address>
        <city>Tallinn</city>
        <zip>13419</zip>
        <country>Estonia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peep Laanmets, MD</last_name>
      <email>Peep.Laanmets@regionaalhaigla.ee</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Helsinki University Central Hospital</name>
      <address>
        <city>Helsinki</city>
        <zip>00029</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kuopio University Hospital</name>
      <address>
        <city>Kuopio</city>
        <zip>70210</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Lahti Central Hospital</name>
      <address>
        <city>Lahti</city>
        <zip>15850</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Heart Hospital Tampere</name>
      <address>
        <city>Tampere</city>
        <zip>33520</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olli Kajander, MD</last_name>
      <email>olli.kajander@sydansairaala.fi</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Turku University Hospital</name>
      <address>
        <city>Turku</city>
        <zip>20521</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cardiovascular Institute, Groupe Hospitalier Mutualiste</name>
      <address>
        <city>Grenoble</city>
        <zip>38000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benjamin Faurie, MD</last_name>
      <email>faurieb@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Arnault Tzanck</name>
      <address>
        <city>Saint Laurent du Var</city>
        <zip>06700</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Bergen University Hospital - Haukeland</name>
      <address>
        <city>Bergen</city>
        <zip>5021</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Germans Trias I Pujol</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Omar A Jawad, MD</last_name>
      <email>oabduljawadaltisent@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Galdakao</name>
      <address>
        <city>Galdakao</city>
        <state>Bizkaia</state>
        <zip>48960</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>José R Rumoroso, MD</last_name>
      <email>rumoroso@me.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Vall de Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital de Bellvitge</name>
      <address>
        <city>Barcelona</city>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Clinico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Javier Escaned, MD</last_name>
      <email>escaned@secardiologia.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital la Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari de Tarragona Joan XXIII</name>
      <address>
        <city>Tarragona</city>
        <zip>43005</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska University Hospital</name>
      <address>
        <city>Gothenburg</city>
        <zip>41345</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dan Iones, MD</last_name>
      <email>dan.ioanes@vgregion.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gävle Hospital</name>
      <address>
        <city>Gävle</city>
        <zip>80325</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Skaane University Hospital (Lund)</name>
      <address>
        <city>Lund</city>
        <zip>22185</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Göran Olivecrona, MD</last_name>
      <email>goran.olivecrona@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Stockholm South Central Hospital (Södersjukhuset)</name>
      <address>
        <city>Stockholm</city>
        <zip>11883</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Belfast Health and Social Care Trust, Department of Cardiology</name>
      <address>
        <city>Belfast</city>
        <zip>BT9 7AB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Bristol</name>
      <address>
        <city>Bristol</city>
        <zip>BS1 3NU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Barts Health NHS</name>
      <address>
        <city>London</city>
        <zip>SW17 0QT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>St George's University Hospital</name>
      <address>
        <city>London</city>
        <zip>SW17 0QT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Estonia</country>
    <country>Finland</country>
    <country>France</country>
    <country>Norway</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>June 10, 2018</study_first_submitted>
  <study_first_submitted_qc>June 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 20, 2018</study_first_posted>
  <last_update_submitted>November 11, 2021</last_update_submitted>
  <last_update_submitted_qc>November 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Aarhus University Hospital Skejby</investigator_affiliation>
    <investigator_full_name>Evald Hoej Christiansen</investigator_full_name>
    <investigator_title>Consultant MD PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

